Market research
6855.HK Ascentage Pharma Group International
HK HKD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 11B
- P/E ratio
- Not available
- Analyst target
- 72.2709
- Dividend yield
- Not available
- Beta
- 0.66
Profile
Instrument facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KYG0519B1023
- Market cap
- 11B
- P/E ratio
- Not available
- Analyst target
- 72.2709
- Dividend yield
- Not available
- Beta
- 0.66
About
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Research context
Ascentage Pharma Group International appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 6855.HK discussion.
5 years, 6 months ago
Ascentage Pharma Group International is currently in a long term uptrend where the price is trading 21.1% above its 200 day moving average.
From a valuation standpoint, the stock is 278.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 425.5.
Ascentage Pharma Group International's total revenue sank by 78.6% to $3M since the same quarter in the previous year.
Its net income has increased by 62.3% to $-319M since the same quarter in the previous year.
Finally, its free cash flow fell by 37.9% to $-280M since the same quarter in the previous year.
Based on the above factors, Ascentage Pharma Group International gets an overall score of 2/5.